<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This paper summarizes results of rhuEPO--treatment obtained by different authors in 27 patients with a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Only 1/3 of <z:hpo ids='HP_0000001'>all</z:hpo> patients with a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were responsive to rhuEPO treatment, while in 2/3 of these subjects no amelioration of <z:hpo ids='HP_0001903'>anaemia</z:hpo> was noticed, even after extremely high doses of this hormone </plain></SENT>
<SENT sid="2" pm="."><plain>A detailed description of a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, which was observed by the authors, is presented </plain></SENT>
<SENT sid="3" pm="."><plain>In this patient the <z:hpo ids='HP_0001903'>anaemia</z:hpo> was refractive even after very high doses of rhuEPO administered for 10 weeks </plain></SENT>
</text></document>